Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SXTP 
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: SXTP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.53% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.75M USD | Price to earnings Ratio 20 | 1Y Target Price 3 |
Price to earnings Ratio 20 | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 2.73 | 52 Weeks Range 1.22 - 12.45 | Updated Date 09/14/2025 |
52 Weeks Range 1.22 - 12.45 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -521.27% |
Management Effectiveness
Return on Assets (TTM) -113.11% | Return on Equity (TTM) -294.87% |
Valuation
Trailing PE 20 | Forward PE - | Enterprise Value 13501014 | Price to Sales(TTM) 5.84 |
Enterprise Value 13501014 | Price to Sales(TTM) 5.84 | ||
Enterprise Value to Revenue 21.05 | Enterprise Value to EBITDA 22.23 | Shares Outstanding 4104470 | Shares Floating 3749884 |
Shares Outstanding 4104470 | Shares Floating 3749884 | ||
Percent Insiders 2.96 | Percent Institutions 12.89 |
Upturn AI SWOT
60 Degrees Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
60 Degrees Pharmaceuticals is a pharmaceutical company focused on developing and commercializing products for infectious diseases. Founded in 2011, it is committed to the discovery, development and delivery of new medicines for infectious diseases.
Core Business Areas
- Infectious Disease Therapeutics: Focuses on developing and commercializing therapeutics for diseases like malaria and other vector-borne illnesses. Includes research, development, and commercialization activities.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure is likely hierarchical, with departments focused on R&D, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Arakoda (tafenoquine): A drug for the prevention of malaria. Market share data is not readily available. Arakoda competes with other malaria preventatives such as Malarone, doxycycline, and mefloquine. Competitors include GlaxoSmithKline and generic manufacturers.
Market Dynamics
Industry Overview
The pharmaceutical industry for infectious diseases is driven by global health needs, particularly in developing countries. Demand is influenced by disease prevalence, travel patterns, and public health initiatives.
Positioning
60 Degrees Pharmaceuticals is positioned as a specialty pharmaceutical company focused on unmet needs in infectious disease prevention and treatment. Its competitive advantage may lie in its focus and expertise in specific disease areas.
Total Addressable Market (TAM)
The TAM for malaria prevention is estimated to be in the billions of dollars, considering the global population at risk. 60 Degrees Pharmaceuticals captures a small proportion of this TAM, with opportunity for growth.
Upturn SWOT Analysis
Strengths
- Specialized expertise in infectious diseases
- Approved product (Arakoda)
- Potential for government and NGO partnerships
Weaknesses
- Limited product portfolio
- Dependence on a single drug for revenue
- Small company size and resources
Opportunities
- Expansion into new markets
- Development of new infectious disease products
- Strategic alliances with larger pharmaceutical companies
Threats
- Generic competition
- Changing regulatory landscape
- Emergence of drug resistance
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Sanofi (SNY)
Competitive Landscape
60 Degrees Pharmaceuticals faces competition from larger pharmaceutical companies with established infectious disease portfolios. Its advantage lies in its specialized focus and potentially in niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to ascertain without financial statements.
Future Projections: Future growth depends on the success of Arakoda and any new products in development. Analyst estimates are not generally available for privately held companies.
Recent Initiatives: Recent initiatives would include commercialization efforts for Arakoda and ongoing R&D for new infectious disease therapies.
Summary
60 Degrees Pharmaceuticals is a specialized pharmaceutical company focused on infectious diseases, primarily malaria prevention with its approved drug Arakoda. Being privately held, publicly available details are limited. The company faces competition from larger players in the industry and its success hinges on the commercial success of Arakoda and development of new products. Potential challenges include generic competition and changing regulations; but it also has opportunities to expand its product line and partner with larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (for competitors)
- Industry Reports
- Medical Journals
Disclaimers:
The information provided is based on publicly available data and general industry knowledge. Financial data for privately held companies is limited and may not be accurate. This analysis is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 60 Degrees Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2023-07-12 | Chairman, CEO & President Dr. Geoffrey Stuart Dow Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.60degreespharma.com |
Full time employees 3 | Website https://www.60degreespharma.com | ||
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.